==============================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-----------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
-----------------------------------
DATE OF REPORT: August 14, 2002
DATE OF EARLIEST EVENT REPORTED: August 14, 2002
RIBAPHARM INC.
(Exact name of registrant as specified in its charter)
DELAWARE 1-31294 95-4805665
(State or other (Commission File Number) (I.R.S. Employer
jurisdiction of Identification Number)
incorporation
or organization)
3300 HYLAND AVENUE
COSTA MESA, CALIFORNIA 92626
(Address of principal executive offices)
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (714) 427-6236
==============================================================================
Item 9. Regulation FD Disclosure.
On August 14, 2002, Ribapharm Inc. ("Ribapharm") filed with the
Securities and Exchange Commission its Quarterly Report on Form 10-Q for
the period ended June 30, 2002. Accompanying such report were
certifications by Ribapharm's Chief Executive Officer, Johnson Y.N. Lau,
and Chief Financial Officer, Thomas Stankovich, pursuant to 18 U.S.C.
ss.1350, as adopted pursuant to ss.906 of the Sarbanes-Oxley Act of 2002.
The text of each of these certifications follows:
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Ribapharm Inc. (the
"Company") on Form 10-Q for the period ending June 30, 2002 as filed with
the Securities and Exchange Commission on the date hereof (the "Report"),
I, Johnson Y.N. Lau, President and Chief Executive Officer of the Company,
certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of
the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of Section 13(a)
or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Company.
/s/ Johnson Y.N. Lau
--------------------
Johnson Y.N. Lau
President and Chief Executive Officer
Dated: August 14, 2002
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Ribapharm Inc. (the
"Company") on Form 10-Q for the period ending June 30, 2002 as filed with
the Securities and Exchange Commission on the date hereof (the "Report"),
I, Thomas Stankovich, Senior Vice President and Chief Financial Officer of
the Company, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant
to ss. 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of Section 13(a)
or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Company.
/s/ Thomas Stankovich
---------------------
Thomas Stankovich
Senior Vice President and Chief Financial Officer
Dated: August 14, 2002
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on behalf of the
undersigned hereunto duly authorized.
Dated: August 14, 2002
RIBAPHARM INC.
By: /s/ Roger D. Loomis, Jr.
------------------------
Name: Roger D. Loomis, Jr.
Title: Senior Vice President, General
Counsel and Secretary